The Challenges Of FDA's Nascent Biosimilars Regime

Law360, New York (November 17, 2010, 5:08 PM EST) -- As we enter the brave new world of biosimilars, the first obstacle for the U.S. Food and Drug Administration and the industry will be developing approval standards. Although biosimilars offer a significant opportunity to potentially reduce the cost of biologics for patients, the significant safety and efficacy issues that are involved will require a comprehensive evaluation by the FDA. Those biosimilar companies who go to the FDA early and often, and who can effectively advocate for the desired approval standards for particular products, will be the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.